LEXINGTON, Mass. -- (BUSINESS WIRE) -- Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that they have been selected as a winner of the GE and NFL Head Health Challenge from more than 400 entries across 27 countries by a panel of leading healthcare experts in brain research, imaging technologies and advocates for the advancement of brain research. This grant provides funding to help further advance development of tests to quickly diagnose traumatic brain injuries through their ultra sensitive Simoa™ technology that measures molecular signatures (biomarkers) of brain injury in blood.
The goal of the Head Health Challenge is to improve the safety of athletes, members of the military and society overall. With this grant, GE and the NFL have singled out Quanterix for its effort to advance the detection and management of mild to moderate traumatic brain injuries. This team will look to help physicians make more accurate diagnoses of brain injuries and better predict long-term prognosis of individuals having undergone acute and repetitive injuries. The Simoa technology will be used to develop and validate biomarkers that quantify disease severity and predict long-term outcomes from repetitive injuries.
“This challenge was a call to action to advance head health research and innovation. The breakthrough ideas submitted will help us better understand brain injuries and the brain overall. We are excited to work with Quanterix to advance research for a blood test that would speed the diagnosis of a concussion and therefore help doctors improve treatment,” said Alan Gilbert, director, global government and NGO strategy, GE healthymagination.
“We are extremely honored to be chosen as a grant recipient for the GE and NFL Head Health Challenge,” said Paul Chapman, CEO of Quanterix. “This is the first time biomarkers will be used as reliable predictors of neurological function and aligns perfectly with the overall goal of this challenge. One of the most promising applications for our Simoa platform is to provide a simple blood test that could speed the diagnosis of a concussion in a clinical setting and on the sidelines in a sports arena, therefore, improving overall treatment. This is another step in that direction.”
Launched in March 2013, the Head Health Challenge is part of the Head Health Initiative: a four-year, $60 million collaboration between GE and the NFL to speed diagnosis, and improve treatment for mild to traumatic brain injury. The initiative also includes a four-year, $40 million research and development program from the NFL and GE intended to evaluate and develop next generation technologies to improve diagnosis and enable targeted treatment therapy for patients with mild to traumatic brain injury.
To learn more about the program, please visit: http://www.ninesights.com/community/nfl-ge-grand-challenge/about#/head-health.
GE (NYSE: GE) works on things that matter. The best people and the best technologies taking on the toughest challenges. Finding solutions in energy, health and home, transportation and finance. Building, powering, moving and helping to cure the world. Not just imagining. Doing. GE works. For more information, visit the company's website at www.ge.com.
About The National Football League
Throughout its history, the NFL has made the health and safety of its players a priority. This commitment extends to football played at all ages, as well as other sports. At the youth level, the NFL’s partnership with the Centers for Disease Control and Prevention and the League’s support for USA Football, including prominently their Heads Up Football initiative, helps parents, coaches, clinicians and athletes understand the signs and symptoms of possible head injuries. The league has successfully advocated for the passage of youth concussion laws in 42 states thus far. Through funding for medical studies, including a $30 million grant to the National Institutes of Health for medical research; collaboration with the military on research and recognizing and reporting potential head injuries; and the work of the NFL’s medical committees, the NFL is committed to supporting and advancing science that will have an impact far beyond football. With a continued emphasis on improved equipment, rules changes, and in-game policies, the NFL fosters a culture that promotes health and safety at every level of the game.
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com/simoa-is-here.